Cancer-associated fibroblasts promote the malignant development of lung cancer through the FOXO1 protein/LIF signaling.

Autor: Shen J; Department of Thoracic Surgery, Jiangsu Cancer Hospital, Nanjing 210009, China., Wu W; School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China., Zhang X; Department of Thoracic Surgery, Jiangsu Cancer Hospital, Nanjing 210009, China., Xie X; CT Room, Jiangsu Cancer Hospital, Nanjing 210009, China., Shen W; CT Room, Jiangsu Cancer Hospital, Nanjing 210009, China., Wang Q; School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China. Electronic address: wangqianghu_wqh@163.com.
Jazyk: angličtina
Zdroj: International journal of biological macromolecules [Int J Biol Macromol] 2024 Sep; Vol. 276 (Pt 2), pp. 133987. Date of Electronic Publication: 2024 Jul 19.
DOI: 10.1016/j.ijbiomac.2024.133987
Abstrakt: This paper aims to investigate the current situation of cancer related fibroblasts promoting malignant development of cancer through FOXO1 protein/LIF signal, and explore the strategy of cancer treatment. Recent studies have shown that the expression of the protein forkhead box O1 (FOXO1) is increased in CAFsCAFs (Cancer-associated fibroblasts). This led researchers to investigate whether FOXO1 is involved in the role of CAFs in lung cancer. The results of the study revealed that FOXO1 is indeed upregulated in CAFs, and it positively regulates the transcription of another protein called LIF. Notably, LIF is also upregulated in both CAFs and lung cancer cells. These changes in protein expression were associated with the overexpression of FOXO1 in CAFs. Conversely, silencing FOXO1 in CAFs suppressed their effects on cancer cells and transplanted tumors. The study revealed that the downregulation of LIFR in cancer cells abolished the impact of CAFs overexpressing FOXO1 on cancer cell behavior. This suggests that the FOXO1/LIF signaling pathway is involved in mediating the malignant development of lung cancer induced by CAFs.
Competing Interests: Declaration of competing interest The authors declare no competing interests.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: